Literature DB >> 2252467

Family interventions for schizophrenia.

N Tarrier1, C Barrowclough.   

Abstract

Studies that have attempted to reduce schizophrenic relapse by the use of family interventions are described. Results from studies that implemented behavioral family interventions with patients who were identified as high risk because of the expressed emotion status of their relatives have demonstrated that relapse rates can be significantly reduced over a 2-year postdischarge follow-up period. A number of ongoing studies, especially those that are investigating the interaction of family interventions and different medication regimes, are also discussed. Areas for further investigation are identified, for example: the use of multiple outcome measures, the use of single-case studies and the development of ideographic assessment measures, the interaction of biological and environmental influences, the alleviation of the burden of care, the involvement of the consumer in services, the development of behavioral formulations and analysis of family engagement and compliance, staff training in intervention methods, and the translation of research results into clinical practice.

Entities:  

Mesh:

Year:  1990        PMID: 2252467     DOI: 10.1177/01454455900144003

Source DB:  PubMed          Journal:  Behav Modif        ISSN: 0145-4455


  3 in total

1.  Cognitive behavioural therapy (CBT) for carers of patients with Parkinson's disease: a preliminary randomised controlled trial.

Authors:  D L Secker; R G Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

Review 2.  The potential impact of the recovery movement on family interventions for schizophrenia: opportunities and obstacles.

Authors:  Shirley M Glynn; Amy N Cohen; Lisa B Dixon; Noosha Niv
Journal:  Schizophr Bull       Date:  2006-03-08       Impact factor: 9.306

3.  Psychoeducation and the family burden in schizophrenia: a randomized controlled trial.

Authors:  Tanveer Nasr; Rukhsana Kausar
Journal:  Ann Gen Psychiatry       Date:  2009-07-28       Impact factor: 3.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.